Our Pipeline

The Kiniksa pipeline has the potential to treat a spectrum of autoinflammatory & autoimmune diseases.

Program & Target Indication Preclin Phase 1 Phase 2 Phase 3 Mkt Rights
Rilonacept

IL-1α & IL-1β
Recurrent Pericarditis Phase 2
Worldwide (excl. Middle East and North Africa)
Mavrilimumab

GM-CSFRα
Giant Cell Arteritis Phase 2-ready
Worldwide
KPL-716

OSMRβ
Prurigo Nodularis / Atopic Dermatitis Phase 1
Worldwide
KPL-045

CD30L
T-cell dependent, B-cell-mediated indications Preclinical
Worldwide
KPL-404

CD40
T-cell dependent, B-cell-mediated indications Preclinical
Worldwide

About Rilonacept

Rilonacept is an approved, subcutaneously-administered, cytokine trap that inhibits the signaling of IL-1α and IL-1β, two soluble cytokines​. There are multiple diseases involving these cytokines where rilonacept may provide benefit, the first of which is in a rare, inflammatory, cardiovascular disease where there are currently no approved therapies. We are planning to initiate a Phase 3 trial of rilonacept in recurrent pericarditis in 2018.

Mavrilimumab

Monoclonal antibody inhibitor of GM-CSF signaling. Studied by MedImmune in over 550 patients in rheumatoid arthritis. Planning a Phase 2 study in Giant Cell Arteritis - an inflammatory disease of blood vessels with unmet need.

KPL-716

Monoclonal antibody inhibitor of both IL-31 and Oncostatin M, cytokines involved in pruritus, Th2 response, fibrosis and barrier dysfunction.

KPL-045

Monoclonal antibody inhibitor of a T-cell co-stimulatory mechanism important in the function of activated T-memory cells.

KPL-404

Monoclonal antibody inhibitor of a central control node of T-cell-dependent, B-cell-mediated humoral adaptive immunity​.